The Blog
Source-aware guides on vendor benchmark methodology, evidence quality, and how to read peptide market signal without overstating certainty.
Amycretin is Novo Nordisk's unimolecular GLP-1 and amylin receptor agonist, now in Phase 3 for obesity in both oral and subcutaneous forms. Here is what the trial data actually show.
SLU-PP-332 is an ERR agonist sold by peptide vendors as an exercise mimetic, but it is a synthetic small molecule, not a peptide, and all efficacy data remain preclinical.
VIP peptide, or vasoactive intestinal peptide, has a real clinical literature, a controversial role in the Shoemaker CIRS protocol, and an unusual FDA Category 1 compounding status in 2026.
SHLP2 peptide is one of the most interesting mitochondrial-derived peptides beyond humanin and MOTS-c. Here is what the research says about its metabolism, Parkinson's disease relevance, and limited vendor-market presence.
Cerebrolysin is not a single peptide. It is a porcine-brain-derived peptide mixture used in over 50 countries, backed by a large but disputed clinical literature, and awkward to place inside the normal U.S. peptide-compounding framework.
The mechanistic case for retatrutide plus cagrilintide is easy to understand. The clinical evidence base is zero. Here is why the stack exists, why the trial gap is probably structural, and why pre-mixed blends make verification harder.
Retatrutide gets the hype, but Lilly's investigational peptide brenipatide is being studied across alcohol use disorder, major depressive disorder, bipolar disorder, smoking relapse, opioid use disorder, and more. Here is what the official trial record actually shows.
Three incretin drugs, three different receptor profiles, and three very different headline weight-loss numbers. Here is the cleanest plain-language comparison of semaglutide, tirzepatide, and retatrutide, plus the nuance people usually skip.
Secretary Kennedy says FDA will remove 12 peptides from Category 2 and begin PCAC review in July 2026. Here is what the official FDA notice confirms, what is scheduled later, and what still is not clear.
Overseas sourcing can be cheaper, but price is not the only variable. Domestic fulfillment, verifiable testing, and location transparency can still matter.
A practical starting list for people who want better peptide YouTube than generic hype, including two channels led by doctors and one strong biohacking educator.
A first-person editorial look at InfiniWell, its physician-formulated positioning, and why the oral BPC-Lx Pro spray stands out as a more convenient alternative to gray-market injectable routes.
A disclosed first-person writeup covering shipping speed, product experience, BAC water convenience, and whether EZ Peptides feels worth the premium.
A practical starting point for understanding peptide categories, vendor noise, evidence quality, and the biggest mistakes beginners make.
A transparent walkthrough of how PeptideBenchmark combines Finnrick and Peptide Critic into one ranked board.
The two source systems do different jobs. This guide explains what each one contributes to the benchmark board.
Benchmark scores can be directionally useful, but they are not the same thing as first-party verification.